+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the TeamBirth quality improvement training program aimed at improving shared decision-making during labor and delivery. This study focuses on reducing cesarean births among first-time mothers with term, singleton, vertex pregnancies, especially Black birthing people. It also aims to enhance patient experience and promote respectful care through patient participation in decision-making on labor units. The study compares the TeamBirth intervention, which uses a train-the-trainer model to support shared decision-making huddles, against usual care practices. Participants will be randomly assigned to either the TeamBirth program or usual care. The evaluation measures outcomes before and after TeamBirth implementation over specific timeframes. Participants will be monitored for cesarean birth rates and shared decision-making levels six months before and three months after the intervention starts. Patient experience is also assessed during these periods. The study includes English or Spanish speaking individuals aged 18 or older who gave birth after laboring. Outcomes focus on both overall and Black birthing people, with follow-up planned until July 2029.

Age: 18Years +FEMALEPhase Not Applicable
22 locations
L

Actively Recruiting

Researchers are conducting a Phase 3 global, multicenter, 52-week open-label extension study to assess the long-term safety and tolerability of KarXT in people with psychosis associated with Alzheimers Disease. This study includes participants who have completed prior related studies, allowing continued evaluation of this treatment over an extended period. Participants receive KarXT capsules in various doses ranging from 202 mg to 66.76.67 mg three times daily. This extension study follows completion of earlier trials and continues treatment for up to 52 weeks to monitor long-term effects and safety. During the study, participants are monitored for treatment-emergent adverse events from the initial dose through 14 days after the last dose, totaling up to 54 weeks. Researchers track serious adverse events and withdrawals due to adverse events. The involvement lasts approximately one year, focusing on safety and tolerability assessments.

Age: 55Years - 90YearsAll GendersPhase 3
432 locations